Page 6 - கண்ணீர் படம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Feb 04, 2021   Consistent with Previously Announced Top-Line TRANQUILITY Run-In Cohort Results, Ocular Redness Selected as Primary Endpoint Tear RASP Levels Reduced After Single Doses of Reproxalap in Run-In Cohort of TRANQUILITY and Selected as Secondary Endpoint for Confirmation of Mechanism of Action   LEXINGTON, Mass. (BUSINESS WIRE) Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the finalization of the design of the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry eye chamber will be the primary endpoint. Approximately 150 dry eye disease patients are expected to be enrolled per arm. The TRANQ

United statesPtoddc bradyExchange commissionAldeyra therapeutics incSecurities exchangeChief executive officerAldeyra therapeuticsScavenger receptorPrivate securities litigation reform actSecurities exchange actFinancial conditionAnnual reportQuarterly reportOxid med cellLipid peroxidation markersTear film